Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccine responses in giant cell arteritis and polymyalgia rheumatica
NL-OMON51139Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- May 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Humoral immune response to COVID-19 vaccination. Started May 2021; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51139.